We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Súčasné postavenie isavukonazolu v liečbe invazívnych fungálnych infekcií.
- Authors
ZAHORNACKÝ, O.; JARČUŠKA, P.
- Abstract
Significant medical advances in the treatment and management of immunocompromised patients are currently leading to an ever-increasing incidence of invasive fungal infections (IFIs). Due to the limited antifungal treatment options, the management of IFIs remains a major challenge. The novel triazole antifungal drug isavuconazole shows a broader spectrum of activity against Mucorales isolates and represents another option for tackling difficult-to-treat IFIs. Isavuconazole is a second-generation broad-spectrum triazole antifungal primarily used to treat invasive aspergillosis and mucormycosis. In the future, however, it may be a promising option for the treatment of other, rare IFIs (cryptococcosis, infections caused by dimorphic fungi). The article summarizes the basic knowledge and provides a brief overview of the pharmacodynamics, pharmacokinetics, mechanism of action, metabolism, indications and dosage of isavuconazole in clinical practice. It also includes a brief analysis of selected clinical trials (SECURE, ACTIVE, VITAL) and recommendations of individual international societies.
- Publication
Klinická Mikrobiologie a Infekční Lékařství, 2023, Vol 29, Issue 4, p116
- ISSN
1211-264X
- Publication type
Article